Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S, Gatanaga H, Hayashida T, Imahashi M, Minami R, Koga M, Samukawa S, Watanabe D, Fujii T, Tateyama M, Nakamura H, Matsushita S, Yoshino Y, Endo T, Horiba M, Taniguchi T, Moro H, Igari H, Yoshida S, Teshima T, Nakajima H, Nishizawa M, Yokomaku Y, Iwatani Y, Hachiya A, Kato S, Hasegawa N, Yoshimura K, Sugiura W, Kikuchi T. Uno S, et al. Among authors: imahashi m. J Antimicrob Chemother. 2023 Dec 1;78(12):2859-2868. doi: 10.1093/jac/dkad319. J Antimicrob Chemother. 2023. PMID: 37856677
The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, Sugiura W, Iwatani Y. Kitamura S, et al. Among authors: imahashi m. Nat Struct Mol Biol. 2012 Oct;19(10):1005-10. doi: 10.1038/nsmb.2378. Epub 2012 Sep 23. Nat Struct Mol Biol. 2012. PMID: 23001005
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S; Epzicom-Truvada study team. Nishijima T, et al. Intern Med. 2013;52(7):735-44. doi: 10.2169/internalmedicine.52.9155. Epub 2013 Apr 1. Intern Med. 2013. PMID: 23545667 Free article. Clinical Trial.
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk.
Imahashi M, Izumi T, Watanabe D, Imamura J, Matsuoka K, Ode H, Masaoka T, Sato K, Kaneko N, Ichikawa S, Koyanagi Y, Takaori-Kondo A, Utsumi M, Yokomaku Y, Shirasaka T, Sugiura W, Iwatani Y, Naoe T. Imahashi M, et al. PLoS One. 2014 Mar 25;9(3):e92861. doi: 10.1371/journal.pone.0092861. eCollection 2014. PLoS One. 2014. PMID: 24667791 Free PMC article. Clinical Trial.
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group. Pett SL, et al. Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5. Clin Infect Dis. 2016. PMID: 27048747 Free PMC article. Clinical Trial.
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Pett SL, et al. HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13. HIV Med. 2018. PMID: 28703491 Free article. Clinical Trial.
Middle-aged man with symmetrical lesions in his throat.
Imahashi M, Yokomaku Y. Imahashi M, et al. Eur J Intern Med. 2018 Sep;55:e7-e8. doi: 10.1016/j.ejim.2018.02.029. Epub 2018 Mar 2. Eur J Intern Med. 2018. PMID: 29503070 No abstract available.
Discovery of 4-oxoquinolines, a new chemical class of anti-HIV-1 compounds.
Shiroishi-Wakatsuki T, Maejima-Kitagawa M, Hamano A, Murata D, Sukegawa S, Matsuoka K, Ode H, Hachiya A, Imahashi M, Yokomaku Y, Nomura N, Sugiura W, Iwatani Y. Shiroishi-Wakatsuki T, et al. Among authors: imahashi m. Antiviral Res. 2019 Feb;162:101-109. doi: 10.1016/j.antiviral.2018.12.012. Epub 2018 Dec 21. Antiviral Res. 2019. PMID: 30582937 Free article.
40 results